1. Precigen, Inc. (NASDAQ:PGEN)
On May 14, 2026, H.C. Wainwright raised the firm’s price target on Precigen, Inc. (NASDAQ:PGEN) to $11 from $10 and kept a Buy rating on the shares following the company’s Q1 report. The firm said PAPZIMEOS sales comfortably exceeded guidance.
Citizens also raised the firm’s price target on Precigen, Inc. (NASDAQ:PGEN) to $11 from $9 and keeps an Outperform rating on the shares. The firm said it was impressed by the strength of the PAPZIMEOS launch, citing the product’s clinical profile, commercial preparation efforts, and launch execution.
On May 13, 2026, Precigen, Inc. (NASDAQ:PGEN) reported Q1 EPS of (2c), compared to (18c) in the prior-year period. Revenue totaled $23.25M, versus the consensus estimate of $20.8M. CEO Helen Sabzevari said the company was encouraged by the pace of PAPZIMEOS revenue growth as it works to expand commercialization across the U.S. and pursue additional opportunities in international and pediatric markets. Sabzevari also highlighted continued development of PRGN-2009 in HPV-associated cancers as part of the company’s AdenoVerse platform pipeline. CFO Harry Thomasian Jr. said Precigen recognized $21.6M in net PAPZIMEOS revenue during the product’s first full commercial quarter and noted that Q2 has continued to show strong revenue momentum. As of March 31, 2026, the company had $56.7M in cash, cash equivalents, and investments, excluding approximately $25.7M in PAPZIMEOS-related accounts receivable that had not yet been collected. Management said it continues to expect current cash resources and anticipated PAPZIMEOS sales to fund operations through cash flow break-even by the end of 2026.
Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company developing gene and cell therapies focused on immuno-oncology, autoimmune disorders, and infectious diseases.
While we acknowledge the potential of PGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PGEN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 9 Best American Semiconductor Stocks to Buy According to Analysts
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
